Perception and willingness toward second-generation long-acting antipsychotics among patients with schizophrenia: a cross-sectional survey in Fujian, China - Report - MDSpire
Advertisement
Perception and willingness toward second-generation long-acting antipsychotics among patients with schizophrenia: a cross-sectional survey in Fujian, China
Clinical Report: Attitudes and Acceptance of Second-Generation Long-Acting Antipsychotics
Overview
This study assessed the perceptions and willingness of schizophrenia patients in Fujian, China, towards second-generation long-acting injectables (SGA-LAIs). Findings indicate a high overall acceptance rate based on survey results.
Background
Schizophrenia is a chronic mental disorder affecting approximately 1% of the global population, leading to significant healthcare burdens. Nonadherence to oral antipsychotics is prevalent, with studies indicating that 54.5% to 80% of individuals with schizophrenia do not take their medication as prescribed, contributing to relapse and increased healthcare costs. Long-acting injectable antipsychotics (LAIs) are proposed as a solution to improve adherence and treatment outcomes.
Data Highlights
- Positive willingness to use SGA-LAIs: 68.3%
- Negative willingness to use SGA-LAIs: 31.7%
- Prior SGA-LAI experience (OR): 11.11
- Disease course 5-10 years (OR): 2.898
- Disease course >10 years (OR): 3.282
Key Findings
- 68.3% of participants expressed positive willingness to use SGA-LAIs.
- Prior experience with SGA-LAIs significantly increased willingness (OR = 11.11).
- Longer disease course (5-10 years and >10 years) was associated with greater willingness to accept SGA-LAIs.
Clinical Implications
Enhancing doctor-patient communication and providing education about SGA-LAIs may improve acceptance among patients.
Conclusion
The study highlights significant acceptance of SGA-LAIs among schizophrenia patients, with prior experience and disease duration as key influencing factors.
